Imaging Score Predicts Survival in Node-Negative Esophageal Cancer

A temporal lymph node stratification score identifies high-risk patients who may benefit from adjuvant therapy after neoadjuvant treatment.

For Doctors in a Hurry

Clinicians lack reliable methods to identify high-risk patients with pathologically negative lymph nodes after neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma.
This retrospective study analyzed 325 patients with locally advanced esophageal squamous cell carcinoma to develop a temporal lymph node stratification score.
The stratification score achieved a C-index of 0.72 in validation cohorts compared to 0.59 for standard clinical nodal staging.
Researchers concluded that irregular borders and less than 30 percent diameter reduction independently predict nodal involvement and poor survival outcomes.
Patients with scores of 2 or higher may require adjuvant therapy despite having pathologically negative lymph nodes after initial treatment.

Refining Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma

Locally advanced esophageal squamous cell carcinoma remains a significant clinical challenge, typically requiring a multimodal approach that combines neoadjuvant therapy with surgical resection [1]. The integration of immune checkpoint inhibitors with conventional chemotherapy has significantly increased pathological complete response rates, defined as the total disappearance of all invasive cancer in the resected tissue, compared to chemotherapy alone [2, 3]. Despite these improvements in major pathological response and R0 resection (the complete surgical removal of a tumor with no microscopic cancer cells at the margins), a substantial proportion of patients still experience postoperative recurrence or distant metastasis [4, 5]. Current clinical staging often fails to capture the nuanced risk profile of patients who achieve pathologically negative lymph node status after preoperative treatment [6]. To address this gap, a recent retrospective study evaluated whether specific imaging characteristics of lymph nodes over time can refine risk stratification and inform adjuvant therapy decisions for this population.

Identifying Radiographic Predictors of Nodal Involvement

The researchers conducted a retrospective study involving 325 patients with locally advanced esophageal squamous cell carcinoma to identify high-risk subgroups among those who achieved pathologically negative lymph nodes (ypN0) after surgery. By focusing on this specific population, the study sought to determine which patients might still harbor a high risk of recurrence despite the absence of detectable cancer in resected nodes. The investigators utilized multivariable logistic regression within a training cohort to analyze temporal imaging features (radiographic characteristics that change over the course of treatment). Specifically, they examined the largest lymph node identified after neoadjuvant immunochemotherapy to isolate independent predictors of pathologically positive lymph nodes (ypN+), defined as nodes that contain residual cancer cells upon microscopic examination. The multivariate analysis identified three specific radiographic markers that significantly correlated with pathologically positive nodal status. First, the presence of irregular lymph node borders was a significant predictor of residual disease (p < 0.05). Second, the researchers determined that pre-treatment heterogeneity, which refers to variations in tissue density or signal intensity within the node before the initiation of neoadjuvant immunochemotherapy, was strongly associated with ypN+ status (p < 0.05). Finally, a reduction in the longest diameter of the lymph node of less than 30% following neoadjuvant therapy served as a critical indicator of pathologically positive nodes (p < 0.05). For practicing oncologists and surgeons, these findings suggest that specific morphological and size-based changes in lymph nodes during the preoperative period can signal a higher risk of nodal involvement that standard pathological staging might miss.

Development and Validation of the TLNS Scoring System

To translate the identified radiographic predictors into a practical clinical tool, the researchers developed the temporal lymph node stratification (TLNS) score. This scoring system was constructed by taking the significant variables from the multivariable logistic regression analysis (p < 0.05) and rounding the absolute values of their beta coefficients (statistical weights that represent the strength of each predictor's association with pathologically positive lymph nodes). This methodology allowed the investigators to assign a discrete numerical value to each high-risk imaging feature, creating a weighted model that could be easily applied in a clinical setting to assess nodal risk after neoadjuvant immunochemotherapy. The investigators rigorously evaluated the predictive model using several statistical measures to ensure its clinical utility. They employed time-dependent receiver operating characteristic curves (tools used to measure the accuracy of a prediction model at various points during follow-up) along with calibration curves to assess how closely the predicted outcomes matched the actual observed results. Furthermore, the team utilized decision-curve analysis, a method used to determine the clinical net benefit of a predictive model across a range of threshold probabilities, to confirm that the TLNS score could effectively guide treatment decisions without excessive false positives or negatives. The predictive performance of the TLNS score was validated by comparing it directly against the clinical N (cN) stage, which is the standard preoperative assessment of nodal involvement. In the training cohort, the TLNS score demonstrated a higher C-index of 0.66 compared to 0.50 for clinical N staging. The C-index, or concordance index, is a measure of a model's ability to correctly distinguish between patients who experience an event and those who do not. This superior accuracy was confirmed in an external validation cohort, where the TLNS score achieved a C-index of 0.72, substantially higher than the 0.59 recorded for clinical N staging. These data indicate that the TLNS score provides a more precise assessment of nodal risk than traditional staging methods for patients with esophageal squamous cell carcinoma.

Clinical Implications for Adjuvant Therapy Decisions

The researchers utilized the temporal lymph node stratification (TLNS) score to categorize patients with pathologically negative lymph nodes (ypN0) into distinct prognostic risk groups. This stratification is critical because even when surgical pathology shows no evidence of nodal disease after neoadjuvant treatment, a subset of patients remains at high risk for recurrence. The study established a threshold for risk by dividing patients into two specific categories: a high-TLNS group, defined by scores of 2 or greater, and a low-TLNS group, defined by scores of less than 2. This scoring system allows clinicians to look beyond binary pathological results to identify underlying risk based on the radiographic evolution of lymph nodes during neoadjuvant immunochemotherapy. The clinical relevance of this stratification became evident when examining postoperative survival outcomes. The researchers found that high TLNS scores were associated with significantly worse postoperative survival among patients who were pathologically node-negative. Specifically, when analyzing ypN0 patients who did not receive adjuvant therapy (additional treatment given after the primary surgery), those with high TLNS scores had a significantly poorer prognosis than even the ypN+ patients who did receive adjuvant therapy. This finding suggests that radiographic features can signal a high risk of occult microscopic disease or aggressive tumor biology that standard pathological staging might miss, placing these pathologically node-negative patients at a survival disadvantage comparable to those with confirmed nodal involvement. These findings provide a data-driven basis for refining adjuvant therapy decisions in esophageal squamous cell carcinoma. Because high TLNS scores were associated with a potential benefit from adjuvant therapy, the score serves as a predictive marker for identifying which ypN0 patients should be considered for further systemic treatment. While current protocols often omit adjuvant therapy for patients who achieve a pathologically negative nodal status, this study indicates that the high-TLNS subgroup represents a high-risk population that may require more aggressive postoperative intervention to improve survival outcomes. By integrating the TLNS score into clinical practice, physicians can better tailor treatment plans, ensuring that adjuvant therapy is directed toward those most likely to derive a therapeutic benefit.

Study Info

Temporal lymph node imaging features for prognostic risk stratification in neoadjuvant immunotherapy for esophageal cancer: a multicenter study

Tiantian Fan, Xinxin Wang, Funing Chu, Can Yu, et al.

Journal European Radiology

Published April 27, 2026